Personalized cancer therapy hinges upon predicting which patient is more responsive to specific therapies. It is based on the notion that the patient’s genotypes can affect the metabolism and drug toxicity while the tumor biomarkers are the indicators of the effectiveness of the treatment and...
Cell-state change is referred to as a process in which the cell undergoes a change in its state and can range from stem cell differentiation to a change in drug-tolerance. For example, a cancer cell initially prone to inhibitors can develop into a drug-resistant mode....
Rapid and in-time monitoring of disease-specific biomarkers holds a significant value in disease prevention and early treatment. It also is important to monitor these biomarkers post-treatment to make sure of the efficiency of the treatment. A multi-disciplinary team of researchers has recently reported a microfluidic...
Cancer stem cells (CSCs) are a small subpopulation (often 1-3%) within the tumor and are capable to regenerate malignant cells. It is believed that this small subpopulation is responsible for forming tumors. They are highly resistant to drugs and extremely tumorigenic and metastatic. Therefore, a...
Personalized medicine aims at providing individual patients with a therapy tailored to their features. It can significantly increase the body’s response to the medicine and the therapeutic treatments and is even more pronounced in patients with cancer. The two arms of the personalized medicine are...